ASH 2024 | Key updates in hairy cell leukemia from ASH 2024
In this video, Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses two key studies on hairy cell leukemia (HCL) presented at ASH 2024. The first is a trial led by the NCI (NCT00923013) comparing cladribine with either concurrent or delayed rituximab in patients with classic HCL previously treated with a purine analog. The second study, also led by the NCI, examines BRAF mutations in patients with HCL, revealing that while most cases have the BRAF V600E mutation, some do not, and these patients have poorer outcomes with purine analogs alone. Dr Rogers emphasizes the importance of molecular testing to identify BRAF mutations, which could help tailor treatment strategies for better patient outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
